补肾通痹丸、清热通痹丸治疗强直性脊柱炎的疗效观察  

Clinical observation on treating ankylosing spondylitis with Bushen Tongbi Wan and Qingre Tongbi Wan

作　　者：孔祥民[1] 孙娜[1] 周晓妍[1] 温亚蒙 

机构地区：[1]济宁市中医院,山东济宁272000

出　　处：《中医临床研究》2015年第25期47-49,共3页Clinical Journal Of Chinese Medicine

摘　　要：目的:探讨补肾通痹丸、清热通痹丸两种中药丸剂治疗强直性脊柱炎的疗效。方法:选择我院收治的强直性脊柱炎患者300例,随机分为治疗组和对照组,每组各150例,对照组口服柳氮磺吡啶肠溶片、沙利度胺片、洛索洛芬钠胶囊治疗,治疗组分为肾虚督寒和湿热痹阻两型,分别予口服补肾通痹丸、清热通痹丸治疗,比较两组治疗效果。结果:治疗组临床疗效优于对照组,组间资料比较,差异具有统计学意义(P<0.05);治疗组患者治疗后红细胞沉降率和高敏C反应蛋白改善幅度优于对照组,组间对比差异有统计学意义(P<0.05);治疗组不良反应发生率明显低于对照组。结论:补肾通痹丸、清热通痹丸治疗强直性脊柱炎疗效可靠、安全性好、服用方便,值得在临床上推广使用。Objective： To discuss clinical effects of Bushen Tongbi Wan and Qingre Tongbi Wan on ankylosing spondylitis. Methods： 300 cases of ankylosing spondylitis were randomly divided into the treatment group and the control group, 150 cases in each group. The control group were treated with the oral Sulfasalazine Enteric-coated tablets, Thalidomide tablets, Loxoprofen Sodium capsules. The treatment group were divided into the Shenxu Duhan type and the Wenre Bizu type, and were treated with Bushen Tongbi Wan and Qingre Tongbi Wan respectively. The therapeutic effects between two groups were compared. Results： In treatment group the clinical effects was better than that in the control group, with statistically significant difference （P〈0.05）;in the treatment group the erythrocyte sedimentation rate and high sensitive C reactive protein improvement were better than the control group; the difference was statistically significant between two groups （P〈0.05）;in the treatment group the incidence of adverse reaction was significantly lower than the control group. Conclusion：The therapeutic effects of Bushen Tongbi Wan and Qingre Tongbi Wan are good. The therapy is worthy of promotion.

关 键 词：中药 补肾通痹丸 清热通痹丸 强直性脊柱炎 大偻 

分 类 号：R286[医药卫生—中药学]